Renoprotective effects telmisartan in the 5/6 nephrectomised rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 8, Issue 2, 2007, Pages 93-100

  Tsunenari, Ichiro ^a   Ohmura, Tsuyoshi ^a   Seidler, Randolph ^b   Chachin, Motohiko ^a   Hayashi, Toshihiro ^a   Konomi, Ayako ^a   Matsumaru, Takehisa ^a   Sumida, Toshiyuki ^a   Hayashi, Naoyuki ^a   Horie, Yoshiharu ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Angiotensin; Fibrosis; Kidney; TGF ; Vessel

Indexed keywords

ENALAPRIL MALEATE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CELL INFILTRATION; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG EFFICACY; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIUM; KIDNEY INJURY; KIDNEY TUBULE DISORDER; MALE; NEPHRECTOMY; NONHUMAN; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SURVIVAL RATE; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENALAPRIL; KIDNEY; NEPHRECTOMY; RATS;

EID: 34547997251     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2007.017     Document Type: Article

References (40)

1. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346:1145-51.
2. Wolf G. Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease. Nephrol Dial Transplant 1998;13:1131-42.
3. Unger T, Culman J, Gohlke P. Clinical practice. Nephropathy in patients with type 2 diabetes. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998;16(suppl 7):S3-S9.
4. Wienen W, Hauel N, Van Meel JC et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110:245-52.
5. Wienen W, Entzeroth M. Effects on binding characteristics and renal function of the novel, non-peptide angiotensin II antagonist BIBR277 in the rat. J Hypertens 1994;12:119-28.
6. Chachin M, Ohmura T, Hayashi N et al. Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker. Folia Pharmacol Jpn 2004;124:31-9.
7. Barnett AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enaraprIL (DETAIL) study. Acta Diabetol 2005;42:S42-S49.
8. Makino H, Haneda M, Babazono T et al. The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, investigation on type 2 diabetic nephropathy (INNOVATION) study. J Int Med Res 2005;33:677-86.
9. Remuzzi A, Remuzzi G. Potential protective effects of telmisartan on renal function deterioration. JRAAS 2006; 7:185-91.
10. Mandarim-de-Lacerda CA, Pereira LM. Effect of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol Histopathol 2004;19:727-33.
11. Wienen W, Richard S, Champeroux P et al. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. JRAAS 2001;2:31-6.
12. Ohmura T, Tsunenari I, Seidler R et al. Renoprotective effects of telmisartan on renal injury in obese Zucker rats. Acta Diabetol (Submitted).
13. Cibulskyte D, Pedersen M, Hørlyck A et al. Telmisartan attenuates chronic ciclosporin A nephrotoxicity in a pig model. Nephrol Dial Transplant 2007;22:369-75.
14. Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomy. Am J Pathol 1975; 79:95-101.
15. Romero F, Rodriguez-Iturbe B, Parra G et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999;55:945-55.
16. Noda M, Matsuo T, Fukuda R et al. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999; 56:898-909.
17. Hostetter TH, Olson JL, Venkatachalam MA et al. Hyperfiltration of remnant nephrons: A potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
18. Ustundag B, Canatan H, Cinkiline N et al. Angiotensin converting enzyme (ACE) activity levels in insulin-independent diabetes mellitus and effect of ACE levels on diabetic patients with nephropathy. Cell Biochem Funct 2000;18:23-8.
19. Timmermans PB, Duncia JV, Carini DJ et al. Discovery of losartan, the first angiotensin II receptor antagonist. J Hum Hypertens 1995;9(suppl 5):S3-S18.
20. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24:354-65.
21. Wolf G. Angiotensin II as a mediator of tubulointerstitial injury. Nephrol Dial Transplant 2000;15(suppl 6):61-3.
22. Kitamura H. Histopathology of diabetic nephropathy. Jin To Toseki. Kidney and Dialysis 2004;56:298-305.
23. Fleck C, Appenroth D, Jonas P et al. Suitability of 5/6 nephrectomy (5/6 Nx) for the induction of interstitial renal fibrosis in rats - influence of sex, strain, and surgical procedure. Exp Toxicol Pathol 2006;57:195-205.
24. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 2003;64:350-5.
25. Barata K, Yoshida M, Hokao R et al. Sequential alterations in clinical biochemical indicators of renal function in 5/6 nephrectomized rats - basic study for renal toxicity using 5/6 nephrectomized rats. J Toxicol Sci 1998;23:433-42.
26. 1-receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286:F945-F954.
27. Long DA, Price KL, Herrera-Acosta J et al. How does angiotensin II cause renal injury? Hypertension 2004;43:722-3.
28. 1-receptor-mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Am J Physiol Renal Physiol 2004;289:F632-F637.
29. Sugiyama H, Kobayashi M, Wang DH et al. Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice. Nehprol Dial Transplant 2005; 20:2670-80.
30. Gagliardini E, Benigni A. Role of anti-TGF-β antibody in the treatment of renal injury. Cytokine Growth Factor Rev 2006; 17:89-96.
31. Kelly DJ, Zhang Y, Cox AJ et al. Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model. Kidney Int 2006;69:1954-60.
32. Hong SW, Isono M, Chen S et al. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001;158:1653-63.
33. Kelly DJ, Zhang Y, Gow R et al. Tranilast attenuates structure and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 2004;15:2619-29.
34. Breiteneder-Geleff S, Matsui K, Soleiman A et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997; 151:1141-52.
35. Matsui K, Breiteneder-Geleff S, Kerjaschki D. Epitope-specific antibodies to the 43-kD glomerular membrane protein podoplanin cause proteinuria and rapid flattening of podocytes. J Am Soc Nephrol 1998;9:2013-26.
36. Koop K, Eikmans M, Baelde HJ et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003;14:2063-71.
37. Shibata S, Nagase M, Yoshida S et al. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007;49:355-64.
38. Hamar P, Kokeny G, Liptak P et al. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp Nephrol 2007;105:e124-e136.
39. Chung O, Unger T. Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 1998;13:537-40.
40. Ruiz-Ortega M, Ruperez M, Esteban V et al. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5:73-9.